SOCS3 and lung adenocarcinoma: Recombinant SOCS3 delivered in synthetic liposomes inhibits in vitro proliferation and survival of lung adenocarcinoma cells and suppresses the malignant transformation of normal endothelial cells, suggesting its potential as a lung cancer treatment strategy [52].